home / stock / pfe / pfe articles

PFE Articles, Pfizer Inc. - From 12/07/23

Stock Information
Company Name: Pfizer Inc.
Stock Symbol: PFE
Market: NYSE
Website: pfizer.com
Menu
PFE PFE Quote PFE Short PFE News PFE Articles PFE Message Board
Get PFE Alerts

News, Short Squeeze, Breakout and More Instantly...
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst | Benzinga

Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (prima...
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities | Benzinga

Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chie...

Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate | Benzinga

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with pa...

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program | Benzinga

NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of ...
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market | Benzinga

How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in rec...

Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy | Benzinga

Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepr...

Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower | Benzinga

Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide with 391 subjects.&n...
This Twice Daily Weight Loss Drug Has Adverse Side Effects And Pfizer Wants To Discontinue It | Benzinga

Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial investigating its oral weight loss drug Glucagon-like peptide-1 receptor ...

How To Make $500 A Month With Pfizer Stock | Benzinga

Pfizer Inc. (NYSE: PFE) shares closed higher on Wednesday. The company is reportedly discontinuing its pharmaceutical sciences small molecule (PSSM...

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium | Benzinga

-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE&#...
Previous 10 Next 10